The latest data concluded that taking tirzepatide resulted in clinically meaningful and sustained weight loss for at least 3 years, and it also led to limited weight gain.
With an overall odds ratio of 2.30, ROSE-010 appears to have significant benefits over a placebo ( Figure 4 )
Tirzepatide follows a step-up approach, starting low and increasing every four weeks based on tolerance and response
Other rare side effects include nausea, dizziness, or allergic reactions
A study in Cell Metabolism confirmed that the reduction in sleeping metabolic rate and 24-hour energy expenditure was comparable between tirzepatide and placebo groups after adjusting for changes in body weight
Peptides trigger the production of IGF-1, VEGF, FGF, and KGF, all of which promote stem cell activation, dermal papilla proliferation and follicle regeneration